Avai Bio, Inc. · OTC:AVAI
Avai Bio — Investor Presentation (September 2026)
15 slides from Avai Bio's investor presentation, September 2026
Slide 1: Engineering living cells for sustained therapeutic delivery
INVESTOR OVERVIEW Engineering living cells for sustained therapeutic delivery Two Programs • One Encapsulation Platform September 2026 | OTCQB: AVAI
Slide 2: Safe Harbor Statement & Disclaimer
Safe Harbor Statement & Disclaimer This document may include statements by Avaí Bio that constitute “forward-looking statements.” Such statements are often characterized by the terms “may,” “believes,” expects” or “anticipates” and do not reflect facts. Forward-looking statements involve risks, unce
Slide 3: Two programs. One protected-cell platform.
INVESTMENT THESIS Two programs. One protected-cell platform. Avaí Bio combines licensed or collaborative therapeutic cell lines with a shared encapsulation technology and partner-enabled development model. Cell-in-a-Box® INSULINOVA KLOTHONOVA Glucose-responsive Sustained α-Klotho insulin production
Slide 4: Cell therapy's promise depends on solving delivery.
THE CHALLENGE Cell therapy’s promise depends on solving delivery. Therapeutic cells can sense biological signals and secrete needed molecules — but implantation introduces three practical barriers. 01 02 03 IMMUNE REJECTION FUNCTION OVER TIME LOCALIZATION & CONTROL Foreign or modified cells may be C
Slide 5: Cell-in-a-Box creates a protected microenvironment for living cells.
THE SHARED PLATFORM Cell-in-a-Box® creates a protected microenvironment for living cells. Nutrients and oxygen can diffuse inward Therapeutic proteins can diffuse outward Cellulose sulphate capsules contain the living cells A PTFE device keeps ~100 capsules localized and retrievable Platform potenti
Slide 6: Cell-in-a-Box Platform Technology: Novel Encapsulation
Cell-in-a-Box® Platform • Encapsulated live cells can be frozen for 5+ years; when thawed, they recover with approximately Technology +80% viability • Long shelf-life and easily shipped worldwide • Competitor live-cell encapsulation technologies use substances such as alginate – derived from seaweed
Slide 7: Insulinova: pursuing cell-based insulin replacement.
PROGRAM 01 • DIABETES Insulinova: pursuing cell-based insulin replacement. RESEARCH + OPTION AGREEMENT • AUGUST 2026 THE PROGRAM COLLABORATION ARCHITECTURE Stem cell-derived insulin- Ospedale San Raffaele Beta-cell differentiation expertise, personnel and facilities producing beta cells Encapsulated
Slide 8: A large—and growing—need for better diabetes solutions.
MARKET CONTEXT • DIABETES A large—and growing—need for better diabetes solutions. ADULTS AGED 20–79 LIVING WITH DIABETES WORLDWIDE 589M → 853M 2024 2050 projection +45% projected growth WHERE INSULINOVA FITS Insulinova targets Type 1 and insulin-dependent Type 2 diabetes, where the need for reliable
Slide 9: Klothonova: sustained production of the α-Klotho protein.
PROGRAM 02 • AGE-RELATED DISEASES, ANTI-AGING Klothonova: sustained production of the α-Klotho protein. PRECLINICAL DEVELOPMENT LICENSED CELL ASSET DE-RISKING PROGRESS Exclusive worldwide rights to NOV 2025 Exclusive global cell-line license announced Klothea Bio’s proprietary Klotho- producing cell
Slide 10: α-Klotho is a broad biological thesis—requiring focused clinical translation.
SCIENTIFIC + MARKET CONTEXT α-Klotho is a broad biological thesis—requiring focused clinical translation. WHY IT MATTERS DEMOGRAPHIC TAILWIND α-Klotho is associated with kidney, vascular, metabolic, and neurological biology—and circulating levels 1 in 6 decline with age. people worldwide projected t
Slide 11: A partnership architecture designed for capital efficiency.
CORPORATE + DEVELOPMENT STRUCTURE A partnership architecture designed for capital efficiency. Avaí Bio, Inc. Cell-line sourcing • capital • commercialization INSULINOVA KLOTHONOVA 50/50: Avaí Bio + Austrianova 50/50: Avaí Bio + Austrianova Diabetes cell therapy α-Klotho cell therapy Research partner
Slide 12: The next value inflections are technical, measurable, and program-specific.
DEVELOPMENT ROADMAP The next value inflections are technical, measurable, and program-specific. CURRENT POSITION NEXT WORKSTREAMS 1 Demonstrate cell viability, secretion, and functional INSULINOVA response after encapsulation Research + option collaboration established; beta-cell encapsulation evalu
Slide 13: A newly assembled platform with multiple near-term proof points.
WHY AVAÍ BIO • WHY NOW A newly assembled platform with multiple near-term proof points. TWO CELL ASSETS ONE DELIVERY ENGINE VALIDATION AHEAD Access to insulin-producing beta Both programs now have Cell-in-a-Box® provides a shared cells through collaboration and an concrete technical workstreams enca
Slide 14: A focused company orchestrating specialized partners.
LEADERSHIP + OPERATING MODEL A focused company orchestrating specialized partners. PARTNER-ENABLED EXECUTION CHRIS WINTER Chief Executive Officer Austrianova Encapsulation IP, cell biology, GMP-grade products and cell-line development 35+ years across investment banking and commodities; experience w
Slide 15: Two therapeutic programs. One protected-cell platform.
Two therapeutic programs. One protected-cell platform. Advancing cellular therapies for diabetes, age-related diseases and anti-aging avaibio.com • OTCQB: AVAI PUBLIC OVERVIEW • FOR DISCUSSION PURPOSES • FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES